The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1623
May 3, 2021
View Complete Issue         Table of Contents 2019 
Tirbanibulin 1% Ointment (Klisyri) for Actinic Keratosis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Tirbanibulin 1% Ointment (Klisyri) for Actinic Keratosis
May 3, 2021 (Issue: 1623)
Tirbanibulin, a microtubule inhibitor, has been approved by the FDA as a 1% ointment (Klisyri – Almirall) for topical treatment of actinic keratosis of the face or scalp.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Tirbanibulin 1% Ointment (Klisyri) for Actinic Keratosis
Article code: 1623e
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.